>
Fa   |   Ar   |   En
   A phase II study of nab-paclitaxel plus carboplatin in combination with thoracic radiation in patients with locally advanced non-small-cell lung cancer  
   
نویسنده hasegawa t. ,futamura y. ,horiba a. ,yoshida t. ,suzuki t. ,kato t. ,kaito d. ,ohno y. ,iida t. ,hayashi s. ,sawa t.
منبع journal of radiation research - 2016 - دوره : 57 - شماره : 1 - صفحه:50 -54
چکیده    We investigated the efficacy and safety of albumin-bound paclitaxel (nab-ptx) and carboplatin (cbdca) with concurrent radiotherapy for unresectable locally advanced non-small-cell lung cancer (nsclc). patients with stage iii nsclc and an eastern cooperative oncology group performance status of 0 or 1 were eligible. concurrent chemoradiotherapy consisted of weekly administration of nab-ptx (40 mg/m2) plus cbdca (area under the plasma concentration time curve (auc) 2) and thoracic radiotherapy (60 gy/30 fractions) for a total of 6 weeks. after concurrent chemoradiotherapy,patients received an additional two cycles of consolidation phase chemotherapy that consisted of 4-week cycles of nab-ptx (100 mg/m2 on days 1,8 and 15)/cbdca (auc 5 mg/ml/min on day 1). response was evaluated in accordance with the response evaluation criteria in solid tumors. progression-free survival and overall survival were estimated using the kaplan-meier method. toxicity was graded using the national cancer institute common terminology criteria for adverse events. a total of 10 patients were enrolled in this trial between september 2013 and january 2014 from three institutes. the overall response rate was 40.0% and the median progression-free survival was 6.7 months. treatment-related death occurred in two patients. grade 2 or worse severe radiation pneumonitis was observed in all three patients that had the volume of lung receiving at least 20 gy (v20) >30%. the results of this study indicate that no further investigation is warranted into nab-ptx and cbdca with concurrent thoracic radiation for stage iii nsclc with v20 > 30% due to severe toxicity. © 2015 the author 2015.
کلیدواژه Carboplatin; Nab-paclitaxel; Non-small-cell lung cancer; Radiotherapy
آدرس department of respiratory medicine and medical oncology,gifu municipal hospital,7-1 kashima-cho,gifu-shi,gifu 500-8323, Japan, department of respiratory medicine and medical oncology,gifu municipal hospital,7-1 kashima-cho,gifu-shi,gifu 500-8323, Japan, department of respiratory medicine and medical oncology,gifu municipal hospital,7-1 kashima-cho,gifu-shi,gifu 500-8323, Japan, department of respiratory medicine and medical oncology,gifu municipal hospital,7-1 kashima-cho,gifu-shi,gifu 500-8323, Japan, respirtory medicine,national hospital organization nagara medical center,1300-7,nagara,gifu-shi,gifu 502-8558, Japan, respirtory medicine,national hospital organization nagara medical center,1300-7,nagara,gifu-shi,gifu 502-8558, Japan, department of respirology,gifu university graduate school of medicine,1-1 yanagido,gifu-shi,gifu 501-1194, Japan, department of respirology,gifu university graduate school of medicine,1-1 yanagido,gifu-shi,gifu 501-1194, Japan, department of radiology,gifu municipal hospital,7-1 kashima-cho,gifu-shi,gifu 500-8323, Japan, department of radiology,gifu university graduate school of medicine,1-1 yanagido,gifu-shi,gifu 501-1194, Japan, department of respiratory medicine and medical oncology,gifu municipal hospital,7-1 kashima-cho,gifu-shi,gifu 500-8323, Japan
 
     
   
Authors
  
 
 

Copyright 2023
Islamic World Science Citation Center
All Rights Reserved